Anlotinib-containing regimens in HR+ advanced breast cancer after prior CDK4/6 inhibitor progression. Chen Y, Liu B, Chen Z, Huang P, et al. NPJ Breast Cancer 2026 Jun 24. doi: 10.1038/s41523-026-00982.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chen Y, Liu B, Chen Z, Huang P, et al. Anlotinib-containing regimens in HR+ advanced breast cancer after prior CDK4/6 inhibitor progression. NPJ Breast Cancer 2026 Jun 24. doi: 10.1038/s41523-026-00982.
PMID: 42342669